ProSciento, Clinical Research Organization (CRO) Focused on Metabolic Diseases, Institutes Rapid COVID-19 Antigen and Antibody Testing at Clinical Research Unit in Southern California Read More »
ProSciento Appoints Dr. Michael Grimm as Chief Medical Officer Read More »
View Our Presentation
184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers Read More »
Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes Read More »
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption Read More »
